Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco | ||
By: Nasdaq / GlobeNewswire - 15 Feb 2019 | Back to overview list |
|
YARDLEY, Pa., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will present clinical and health economic outcomes data at the 2019 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Francisco, California, February 22 - 25, 2019. Abstracts are available on the AAAAI Annual Meeting website located at annualmeeting.aaaai.org. XHANCE® (fluticasone propionate) nasal spray, 93 mcg, is approved by the U.S. Food and Drug Administration for the treatment of nasal polyps in patients 18 years of age or older. Data on XHANCE, trade name for the Exhalation Delivery System with fluticasone (EDS-FLU), is expected to be highlighted in four scientific posters presented during the AAAAI Annual Meeting: Poster Session #2213 is scheduled on Saturday, February 23 from 9:45 a.m. to 10:45 a.m. in the Moscone Center South, Hall B.
Poster Session #4210 is scheduled on Monday, February 25 from 9:45 a.m. to 10:45 a.m. in the Moscone Center South, Hall B.
Poster Session #4212 is scheduled on Monday, February 25 from 9:45 a.m. to 10:45 a.m. in the Moscone Center South, Hall B.
The poster presentations are intended for scientific discussion only. About Optinose Optinose Investor Contact |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |